Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alexander N. Starodub
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-Sn-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Cancer
Cancer Research
Oncology
Related publications
Synthetic Lethality Exploitation by an Anti–Trop-2-Sn-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –Wild-Type Triple-Negative Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Milatuzumab-Sn-38 Conjugates for the Treatment of CD74+ Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
Insulin Receptor Antibody-Iduronate 2-Sulfatase Fusion Protein: Pharmacokinetics, Anti-Drug Antibody, and Safety Pharmacology in Rhesus Monkeys
Biotechnology and Bioengineering
Applied Microbiology
Biotechnology
Bioengineering
An Anti-Cd133 Monoclonal Antibody CMab-43 Exerts Anti-Tumor and Anti-Metastasis Activities for Colon Cancers
Proceedings for Annual Meeting of The Japanese Pharmacological Society
Studies on Antibody-Anticancer Drug Conjugate
Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-Cd38 Cytolytic Antibody TAK-079 in Healthy Subjects
British Journal of Clinical Pharmacology
Pharmacology
Intracellular Catabolism of an Antibody Drug Conjugate With a Noncleavable Linker
Drug Metabolism and Disposition
Pharmacology
Pharmaceutical Science
MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity
Molecular Cancer Therapeutics
Cancer Research
Oncology
